Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that its topical drug DB-007-5 was highly effective at treating atopic dermatitis (AD) and is more potent at reducing itch than the current leading AD drug in a […]
Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company developing safe and highly effective topical treatments for inflammatory skin diseases and skin conditions, is pleased to announce that it has added acne and acne scarring expert Dr. Jerry Tan to its Scientific Advisory Board. Acne is a persistent […]
Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevity
VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy aging, is excited to announce the development of a novel, science-backed skincare treatment aimed at targeting some of the root causes of skin aging, such as chronic inflammation and cellular damage. Derm-Biome’s compounds exhibit a broad range of beneficial effects, including anti-inflammatory, antioxidant, and […]
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to announce that, in partnership with TransBIOtech (Quebec), is being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the […]
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) — The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 million Americans a year developing this condition. Treating AKs before the cells become cancerous and spread to other parts of the body is crucial. For those patients with multiple AKs, common treatment options are […]
Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin diseases and skin cancer, is pleased to announce that it will soon begin a GLP toxicology study for DB-007-4, a potential best-in-class, first line topical treatment for inflammatory skin diseases such as acne, atopic […]
Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study
…
Derm-Biome Pharmaceuticals to Present at the 2023 OBIO Investment Summit on February 10, 2023
…
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne
…
Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole
…